{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006602","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.196455+00:00","generated_at":"2026-05-22T08:19:23.801463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction","bullets":["Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.","Net loss $50.8M ($0.81 per share) vs $141.4M ($2.35) YoY; R&D down due to prior-year acquisition cost.","Phase 3 TRANSCEND trial met primary endpoint: -19.8% placebo-adjusted BMI reduction at 52 weeks (p<0.0001); no new safety signals.","Cash and investments $314.5M as of March 31, 2025; cash runway into 2027.","Fiscal 2025 Non-GAAP operating expense guidance $285M-$315M; regulatory submissions for HO in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006602","json":"https://secwatch.observer/filing/0001558370-25-006602.json","markdown":"https://secwatch.observer/filing/0001558370-25-006602.md","text":"https://secwatch.observer/filing/0001558370-25-006602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/0001558370-25-006602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:19:23.801463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}